UnitedHealth Group saw its stock drop 20% after it cut its annual profit outlook, citing a steep rise in medical costs tied to its Medicare Advantage plans. This move, coming from the largest player in the Medicare Advantage market, triggered industry-wide concerns. Competitors also took hits, with shares of Humana falling 5%, Elevance Health over 1%, and CVS down 2%. Only Cigna saw a slight gain, as it does not participate in the Medicare Advantage space.
The company’s revised forecast came amid a broader industry reckoning. Health insurers have been struggling with a difficult year marked by lower government payments, increasing utilization of healthcare services, and heightened public scrutiny following the tragic death of UnitedHealthcare’s CEO, Brian Thompson.
TD Cowen’s analysts described UnitedHealth’s quarterly results as showing “ominous signs” of worsening costs. While the company had already warned in 2023 that expenses could increase, the magnitude now observed appears to be far higher than expected. First-quarter data revealed that the use of medical services—especially doctor visits and outpatient procedures—rose to nearly double what UnitedHealth had initially anticipated for 2025.
The spike in care usage is partly due to seniors returning for treatments like hip and joint replacements that were postponed during the pandemic. This surge in utilization has challenged insurers across the board, although it had not previously impacted UnitedHealth to this extent.
Some analysts noted that the pressure may be less intense for insurers that withdrew from less profitable Medicare Advantage markets in 2024, including Humana and CVS. Conversely, companies that expanded their Medicare Advantage footprint, like Elevance Health and Alignment Health, may face increased vulnerability.
UnitedHealth executives pointed to changes within their Optum division as another complicating factor. Optum handles a range of services, including pharmacy benefit management, and has seen a shift in the patient profile that is affecting performance. Despite the current challenges, the company expressed confidence in addressing the issues before 2026.
A potential silver lining for insurers is the recent announcement from the Trump administration to significantly increase Medicare Advantage reimbursement rates for 2026, reversing a previous proposal and offering some hope for future margins.
READ MORE: